United Statescytivalifesciences.com
Its role Technology / equipment supplier
Cytiva is a global life sciences company, part of Danaher, that supplies technologies, consumables, and services used to discover, develop, and manufacture biopharmaceuticals. Created in 2020 from the former GE Healthcare Life Sciences biopharma business, it supports customers from early research through clinical development and commercial production.
The company’s portfolio includes chromatography resins and systems, filtration and purification solutions, single‑use bioprocess equipment (such as bioreactors, mixers, and fluid management components), cell culture media and related hardware, as well as process analytics and automation software. Cytiva serves pharmaceutical and biotechnology companies, contract development and manufacturing organizations, and academic and government laboratories, with an emphasis on scalable and compliant bioprocessing.
chemXplore tracks 1 project involving Cytiva, of which one is active.
1 more active project is in the record. See all 1 in chemXplore →
Yokohama technical center began cell therapy process development in July 2025 and has been awarded multiple exosome and T‑cell projects, including a program transferred from Milan.
Deal covers commercial manufacturing of multiple biopharmaceuticals using new Yokohama site; revenue expected at several tens of billions of yen; GMP services targeted for 2027.
A UK consortium receives £7M to develop bio-based solvents, aiming to cut pharmaceutical emissions by 60% and streamline adoption without major infrastructure changes.
Cytiva adopts renewable polypropylene to cut Scope 3 emissions, ensuring high performance in healthcare applications with ISCC PLUS-certified materials.
active all projects
